Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bio Detection K9 was a private U.S. bio-detection company focused on training canines and using related protocols and technology to detect pathogens in human and agricultural settings. The company positioned itself as a leader in canine detection of bacteria, viruses, and COVID-19, and also pursued precision agriculture applications such as plant pathogen screening. Its offerings were service-based rather than a traditional therapeutic drug pipeline, combining trained dogs, lab-supported training materials, and operational deployment programs. Bio Detection K9 was acquired by Priority One Canine in September 2021, and third-party databases subsequently listed the company as closed following the acquisition.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bio Detection K9.